BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17116620)

  • 1. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
    Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
    Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
    Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
    Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gastrointestinal stromal tumour: our experience].
    Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
    Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of complete response after imatinib mesylate treatment of advanced GIST.
    Papaxoinis G; Nikolaou M; Lianos E; Gaglia A; Economopoulos T; Pectasides D
    Anticancer Res; 2006; 26(6C):4869-72. PubMed ID: 17214353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
    Kasper B; Kallinowski B; Herrmann T; Lehnert T; Mechtersheimer G; Geer T; Ho AD; Egerer G
    Dig Dis; 2006; 24(1-2):207-11. PubMed ID: 16699280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
    Armbrust T; Sobotta M; Gunawan B; Füzesi L; Langer C; Cameron S; Ramadori G
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):819-23. PubMed ID: 19369884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.